Research programme: solid tumour therapeutics - NanoSmart

Drug Profile

Research programme: solid tumour therapeutics - NanoSmart

Alternative Names: Autoimmune antinuclear antibodies - Nanosmart; Ewing's sarcoma therapeutics - NanoSmart/Children's Hospital Los Angeles; Human derived antinuclear antibodies - Nanosmart; Tumour necrosis targeted antibodies - NanoSmart

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NanoSmart Pharmaceuticals
  • Developer Childrens Hospital Los Angeles; NanoSmart Pharmaceuticals
  • Class Antibodies; Immunoconjugates
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ewing's sarcoma; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Ewing's Sarcoma in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in USA
  • 30 Jul 2015 NanoSmart's dactinomycin based drug formulation receives Orphan Drug status for Ewing's Sarcoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top